Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F20%3A10412029" target="_blank" >RIV/00216208:11140/20:10412029 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/20:10412029

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pWiMG0leap" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pWiMG0leap</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3892/ol.2020.11663" target="_blank" >10.3892/ol.2020.11663</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib

Popis výsledku v původním jazyce

Erlotinib is used mainly in patients with sensitizing EGFR mutations. In clinical practice, erlotinib is also used in non-mutated patients in higher lines of treatment. However, there is no predictive marker for efficacy of erlotinib in wild-type (wt) patients. Immunohistochemical (IHC) parameters such as the thyroid transcription factor 1 (TTF1) or p63 have been shown to possibly have the predictive power. When IHC parameters were ignored, our cohort of 679 patients showed the same efficacy of erlotinib in both squamous lung cancer and adenocarcinoma. However, we found significant differences in progression free survival (PFS) and overall survival (OS) in a subgroup of 126 patients where these parameters were known. In a univariate analysis, the group A (TTF1 positive and p63 negative adenocarcinomas) achieved PFS of 2.6 months, the group B (TTF1 negative and p63 positive squamous carcinomas) 1.9 months and the group C (did not fall into either A or B) 1.4 months (p = 0.006). Median OS was 14.2, 19.1 and 5.3 months for A, B and C, respectively (p = 0.002). A multivariate analysis then demonstrated IHC markers to be the only significant parameters for both PFS and OS. The group C was a negative prognostic factor for PFS (HR = 1.81, p = 0.02) and OS (HR = 2.37, p = 0.008). In conclusion, EGFR wt patients with lung carcinomas without the TTF1 and p63 expression typical for adenocarcinomas (ADC) and squamous cell carcinomas (SCC) do not appear to be suitable candidates for erlotinib treatment.

Název v anglickém jazyce

Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib

Popis výsledku anglicky

Erlotinib is used mainly in patients with sensitizing EGFR mutations. In clinical practice, erlotinib is also used in non-mutated patients in higher lines of treatment. However, there is no predictive marker for efficacy of erlotinib in wild-type (wt) patients. Immunohistochemical (IHC) parameters such as the thyroid transcription factor 1 (TTF1) or p63 have been shown to possibly have the predictive power. When IHC parameters were ignored, our cohort of 679 patients showed the same efficacy of erlotinib in both squamous lung cancer and adenocarcinoma. However, we found significant differences in progression free survival (PFS) and overall survival (OS) in a subgroup of 126 patients where these parameters were known. In a univariate analysis, the group A (TTF1 positive and p63 negative adenocarcinomas) achieved PFS of 2.6 months, the group B (TTF1 negative and p63 positive squamous carcinomas) 1.9 months and the group C (did not fall into either A or B) 1.4 months (p = 0.006). Median OS was 14.2, 19.1 and 5.3 months for A, B and C, respectively (p = 0.002). A multivariate analysis then demonstrated IHC markers to be the only significant parameters for both PFS and OS. The group C was a negative prognostic factor for PFS (HR = 1.81, p = 0.02) and OS (HR = 2.37, p = 0.008). In conclusion, EGFR wt patients with lung carcinomas without the TTF1 and p63 expression typical for adenocarcinomas (ADC) and squamous cell carcinomas (SCC) do not appear to be suitable candidates for erlotinib treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Oncology Letters

ISSN

1792-1074

e-ISSN

—

Svazek periodika

20

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

7

Strana od-do

1376-1382

Kód UT WoS článku

000563832100043

EID výsledku v databázi Scopus

2-s2.0-85087210919